Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)
A De Soyza, T Aksamit, TJ Bandel, M Criollo, JS Elborn, E Operschall, E Polverino, K Winthrop, R Wilson · Pneumologie · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Background: RESPIRE 1, an international Phase III trial, aimed to evaluate if Ciprofloxacin DPI as long-term, intermittent therapy in bronchiectasis patients (non-CF etiology) with ≥2 exacerbations (prior 12 months) and respiratory pathogens reduces exacerbations and improves quality-of-life (QoL). We investigated concomitant treatment use at baseline in different countries. Methods: We analysed preliminary baseline demographics, disease characteristics, and treatment use of subjects randomised in RESPIRE1 by country. Countries that contributed > 1% of the full cohort were evaluated for numerical differences in…
